Welcome to our dedicated page for Scilex Holding Co news (Ticker: SCLX), a resource for investors and traders seeking the latest updates and insights on Scilex Holding Co stock.
Scilex Holding Company (Nasdaq: SCLX) generates frequent news at the intersection of non-opioid pharmaceuticals, capital markets activity, and emerging data-tokenization initiatives. The company focuses on acquiring, developing and commercializing non-opioid pain management products for acute and chronic pain and for neurodegenerative and cardiometabolic disease, and its updates often center on this portfolio and related strategic moves.
News about Scilex commonly covers developments around its commercial products ZTlido, ELYXYB and Gloperba, as well as its late-stage candidates SP-102 (SEMDEXA), SP-103 and SP-104. Company announcements highlight clinical milestones, regulatory designations such as Fast Track status for certain candidates, and efforts to advance non-opioid therapies in indications with high unmet needs.
Investors following SCLX news will also see regular coverage of financing and corporate transactions. Recent Form 8-K filings and press releases describe warrant inducement agreements, exercises of existing warrants for cash proceeds, issuance of new warrants, non-recourse loan and securities pledge agreements backed by Scilex or Datavault AI shares, and the termination of an equity line of credit. These items provide insight into how Scilex structures its capital and manages liquidity.
Another recurring news theme is Scilex’s collaboration with Datavault AI. Announcements describe a Securities Purchase Agreement for Datavault AI stock, a pre-funded warrant, and a License Agreement for Datavault’s AI-driven data platforms in biotech and related markets. Press releases also detail Dream Bowl 2026 Meme Coin distributions by Datavault AI to eligible Scilex shareholders and Scilex’s sponsorship of the Dream Bowl 2026 event.
Visitors to this news page can review regulatory disclosures, financing updates, licensing and investment agreements, digital asset-related announcements, and other material events reported in Scilex’s press releases and SEC filings.
Scilex Holding Company (SCLX) has postponed its 2023 Annual Meeting of Stockholders, originally scheduled for April 6, 2023, to April 17, 2023, due to significant underreporting of over 44 million shares of common stock by brokerage firms. This decision follows a court order from the U.S. Bankruptcy Court compelling these firms to provide information regarding stock ownership related to a recent dividend of 76 million shares of Scilex stock held by its parent company, Sorrento Therapeutics. Compliance with the court's order is expected to allow the underreported shares to participate in the Annual Meeting, potentially impacting shareholder votes and corporate governance.
Sorrento Therapeutics (OTC: SRNEQ) announced a court order on April 4, 2023, requiring top brokers to disclose information regarding Scilex Holding Company (NASDAQ: SCLX) shares amidst its Chapter 11 proceedings initiated on February 13, 2023. This follows Sorrento's December 30, 2022, dividend announcement of 76 million Scilex shares, which brokerages have not reported to Broadridge Financial Solutions for Scilex's upcoming shareholder meeting on April 6, 2023. Sorrento seeks to maximize stakeholder value while navigating its bankruptcy case, with Scilex not being a debtor in the proceedings.
Scilex Holding Company (Nasdaq: SCLX) announced that over 44 million shares of its common stock remain unreported by brokerage firms for the upcoming Annual Meeting on April 6, 2023. This widespread under-reporting could lead to legal challenges, as it violates obligations under federal law. Scilex is coordinating with regulatory agencies to address these violations and protect stockholder voting rights. The company also clarified that all holders of Scilex common stock, including the Dividend Stock, are entitled to vote. Scilex urges stockholders to contact their brokers to demand delivery of proxy materials.
Scilex Holding Company (Nasdaq: SCLX) has entered into a securities purchase agreement to issue and sell unsecured convertible debentures worth up to $25 million. The funds will be allocated to enhance the launch of three FDA-approved non-opioid pain management products: ZTlido®, Gloperba®, and ELYXYB™. The debentures will be issued in three tranches, with the first $10 million available upon signing. The interest rate is set at 7.00%, maturing in December 2023. Scilex aims to accelerate commercialization efforts to address the unmet needs in pain management, as current opioid options are increasingly viewed as ineffective.
Scilex Holding Company (SCLX) has partnered with CH Trading Group as the exclusive distributor for ZTlido® in the Middle East and North Africa, committing to a minimum purchase of US $105 million over five years. This agreement opens access to greater markets, including the broader Islamic world, and allows for potential future distribution of Scilex's non-opioid pain management products. The pain management market is projected to reach US $101.27 billion by 2029, growing at 4.3% CAGR. ZTlido®, designed for neuropathic pain relief, offers improved adhesion and sustained pain relief for 12 hours.
Scilex Holding Company (Nasdaq: SCLX) has officially launched ELYXYBTM, the only FDA-approved oral solution for the acute treatment of migraines in adults. With an estimated U.S. oral migraine drug market size of $1.8 billion in 2022, the company sees significant revenue potential. The re-launch strategies include over 6,000 engagements with potential customers and multiple promotional efforts. Scilex is negotiating a distribution agreement for ELYXYBTM and has a specialized sales force targeting over 80% of physicians. This product diversifies Scilex's pain management portfolio and enhances cash flow and earnings through non-opioid solutions.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced that the U.S. Bankruptcy Court granted interim approval for $75 million debtor-in-possession financing from JMB Capital Partners as part of its Chapter 11 proceedings initiated on February 13, 2023. This financing ensures continued business operations, including employee wages. Sorrento possesses approximately $1 billion in assets but sought Chapter 11 to protect its business from litigation risks. Meanwhile, Scilex Holding Company (Nasdaq: SCLX), Sorrento's majority-owned subsidiary, is not affected by the bankruptcy, continuing its focus on non-opioid pain management products.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced the U.S. Bankruptcy Court approved its employee wages motion and interim cash management motion following its Chapter 11 filing on February 13, 2023. This approval allows the company to maintain normal operations while safeguarding its business, which includes over $1 billion in assets. Sorrento aims to protect stakeholder value amid ongoing litigation. Notably, Scilex Holding Company (Nasdaq: SCLX), a majority-owned subsidiary, remains unaffected by Sorrento's bankruptcy and continues to operate and develop non-opioid pain management products.
Sorrento Therapeutics announced on February 16, 2023, that the U.S. Bankruptcy Court for the Southern District of Texas approved its motions for employee wages and interim cash management, following its Chapter 11 petition filed on February 13, 2023. The company, which has over $1 billion in assets, seeks to protect its business amidst litigation risks. Scilex Holding Company, a majority-owned subsidiary, is not a debtor in this process and continues its operations focusing on innovative pain management products. CEO Henry Ji stated that these motions will help maintain normal operations and support the development of new therapies.